OSE Immunotherapeutics
Update in progressOSE.PA (Paris)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
OSE Immunotherapeutics is a clinical‑stage biotechnology company developing immunotherapies for immune-oncology and immune inflammation, based in Nantes, France. Its programs include Tedopi in Phase III for non‑small cell lung cancer (and Phase II in pancreatic/ovarian cancer); OSE‑279 (Phase I/II solid tumors/lymphomas); OSE‑127 (Phase II for ulcerative colitis and Sjögren’s); FR104 (Phase I for rheumatoid arthritis). It also explores BI‑765063, OSE‑230, CLEC‑1, and BiCKI, with many collaborations globally. Formerly OSE Pharma (2012).
Company score
- Sentiment
- -0.01
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.13
- Governance
- 0.28
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.05
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section